1. Machine learning models can accurately predict intermediate states of brain diseases, enabling earlier diagnosis and treatment. By analyzing large-scale datasets, machine learning algorithms can identify patterns and biomarkers associated with disease progression, allowing for the development of predictive models that can inform clinical decision-making.

2. Intermediate brain disease state prediction using machine learning has the potential to improve patient outcomes by enabling personalized treatment approaches. By identifying patients at risk for disease progression, healthcare providers can tailor treatment plans to the individual, potentially improving efficacy and reducing adverse effects.

3. Machine learning can help identify novel biomarkers and risk factors associated with brain disease progression. By analyzing large-scale datasets, machine learning algorithms can identify previously unknown relationships between variables, providing insights into the underlying biology of brain diseases and potential targets for intervention.

4. The development of accurate and reliable intermediate brain disease state prediction models is critical for the development of effective disease-modifying therapies. By enabling earlier diagnosis and identification of patients at risk for disease progression, these models can support clinical trials and accelerate the development of novel treatments for brain diseases.

Description:Title:
Intermediate brain disease state prediction using Machine
Learning

Field of the Invention

[0001] The present invention is related to the computer science and machine learning field.

Background

[0002]. The use of machine learning for brain disease state prediction has emerged as an active area of research in recent years.
[0003] Brain diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis are complex and multifactorial, making their diagnosis and treatment challenging. Machine learning algorithms have the potential to improve the accuracy and reliability of disease diagnosis and prognosis by analyzing large-scale datasets and identifying patterns and biomarkers associated with disease progression.
[0004]. The application of machine learning techniques for brain disease state prediction is supported by recent advances in neuroimaging and other high-throughput technologies, which allow for the collection of large and complex datasets.

[0005]. Machine learning algorithms such as support vector machines, decision trees, and neural networks have been successfully applied to brain disease state prediction. These algorithms allow for the development of complex models that can account for multiple variables and non-linear relationships between them.
[0006]. Overall, the use of machine learning for brain disease state prediction represents an exciting opportunity to improve our understanding of the underlying biology of brain diseases and develop more personalized and effective treatment approaches.
[0007] In some embodiments, the numbers expressing quantities of ingredients, properties such as concentration, reaction conditions, and so forth, used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term “about.” Accordingly, in some embodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in some embodiments of the invention may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0008] As used in the description herein and throughout the claims that follow, the meaning of “a,” “an,” and “the” includes plural reference unless the context clearly dictates otherwise. Also, as used in the description herein, the meaning of “in” includes “in” and “on” unless the context clearly dictates otherwise.
[0009] The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. “such as”) provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non- claimed element essential to the practice of the invention.
[0010] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

Objects of the Invention

[0011] To develop accurate and reliable models that can assist in early detection and diagnosis of neurological diseases such as Alzheimer's, Parkinson's, and Multiple Sclerosis.
[0012] To identify patients who may be at risk of developing neurological diseases, allowing for earlier intervention and better outcomes

 
Drawings

Figure 1

Brief Description of the Drawing

[0013] The figure 1 represents working model in the present invention with its prototype.
 
Detailed Description:

[0014] In figure 1, showing the input parameter; prediction model by the system 100.

[0017] The present invention takes the input predicts the disease of the using legacy of datasets.
[0018]. The first step is to collect high-quality datasets that capture longitudinal changes in disease states over time. This can include clinical trials, neuroimaging studies, and electronic health records. Once the data is collected, it needs to be preprocessed to remove any noise, missing values, or outliers
[0019]. The next step is to extract relevant features from the preprocessed data. This can involve using techniques such as principal component analysis, wavelet analysis, or time-series analysis to identify features that are most relevant to disease progression. Once the features are extracted, a feature selection algorithm can be used to identify the most informative features for prediction
[0020] . With the relevant features identified, the next step is to develop a predictive model using machine learning algorithms such as support vector machines, decision trees, or neural networks. The model is trained on the preprocessed data using a training set, and the performance of the model is evaluated on a validation set.
[0021] . Once the model is trained, its performance needs to be validated on an independent dataset to ensure that it is generalizable and not overfitting to the training data. The model can then be optimized using techniques such as cross-validation, hyperparameter tuning, or ensemble learning to improve its performance.
[0022] In an aspect, any or a combination of machine learning mechanisms such as decision tree learning, Bayesian network, deep learning, random forest, supervised vector machines, reinforcement learning, prediction models, Statistical Algorithms, Classification, Logistic Regression, Support Vector Machines, Linear Discriminant Analysis, K- Nearest Neighbours, Decision Trees, Random Forests, Regression, Linear Regression, Support Vector Regression, Logistic Regression, Ridge Regression, Partial Least-Squares Regression, Non-Linear Regression, Clustering, Hierarchical Clustering – Agglomerative, Hierarchical Clustering
– Divisive, K-Means Clustering, K-Nearest Neighbours Clustering, EM (Expectation Maximization) Clustering, Principal Components Analysis Clustering (PCA), Dimensionality Reduction, Non-Negative Matrix Factorization (NMF), Kernel PCA, Linear Discriminant Analysis (LDA), Generalized Discriminant Analysis (kernel trick again), Ensemble Algorithms, Deep Learning, Reinforcement Learning, AutoML (Bonus) and the like can be employed to learn sensor/hardware components.
[0023] The term “non-transitory storage device” or “storage” or “memory,” as used herein relates to a random access memory, read only memory and variants thereof, in which a computer can store data or software for any duration.
[0024] It should be apparent to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. The inventive subject matter, therefore, is not to be restricted except in the spirit of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms “comprises” and “comprising” should be interpreted as referring to elements, components, or steps in a non-
exclusive manner, indicating that the referenced elements, components, or
steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced. Where the specification claims refer to at least one of something selected from the group consisting of A, B, C …. and N, the text should be interpreted as requiring only one element from the group, not A plus N, or B plus N, etc.
, Claims:1. Machine learning models can accurately predict intermediate states of brain diseases, enabling earlier diagnosis and treatment. By analyzing large-scale datasets, machine learning algorithms can identify patterns and biomarkers associated with disease progression, allowing for the development of predictive models that can inform clinical decision-making.

2. Intermediate brain disease state prediction using machine learning has the potential to improve patient outcomes by enabling personalized treatment approaches. By identifying patients at risk for disease progression, healthcare providers can tailor treatment plans to the individual, potentially improving efficacy and reducing adverse effects.

3. Machine learning can help identify novel biomarkers and risk factors associated with brain disease progression. By analyzing large-scale datasets, machine learning algorithms can identify previously unknown relationships between variables, providing insights into the underlying biology of brain diseases and potential targets for intervention.

4. The development of accurate and reliable intermediate brain disease state prediction models is critical for the development of effective disease-modifying therapies. By enabling earlier diagnosis and identification of patients at risk for disease progression, these models can support clinical trials and accelerate the development of novel treatments for brain diseases.